PRİMER YUMURTALIK YETMEZLİĞİ OLAN KADINLARDA İNTRAOVARYAN PRP ENJEKSİYONUNUN YUMURTALIK REZERVİ VE IVF SONUÇLARI ÜZERİNDEKİ ETKİLERİ

Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency

Following Ovarian injection of PRP prepared with T-LAB PRP kit in 311 patients suffering from Primary Ovarian Insufficiency where 186 had an antral follicle count of ‘0’; only 87 patients (27,8%) had no antral follicle while 64,8% experienced an improvement in terms of antral follicle count. 82 (26,4% ) of patients developed embryos, 25 of which opted for embryo cryopreservation. As a result of the treatment, 25 women achieved livebirth or sustained implantation.

Abstract: We aimed to determine whether intraovarian injection of autologous platelet rich plasma (PRP) improves response to ovarian stimulation and in vitro fertilization (IVF) outcome in women with primary ovarian insufficiency (POI). Women (N=311; age 24-40) diagnosed with POI based on ESHRE criteria underwent intraovarian PRP injection. Markers of ovarian reserve, and IVF outcome parameters were followed. PRP treatment resulted in increased antral follicle count (AFC) and serum antimullerian hormone (AMH), while serum follicle stimulating hormone (FSH) did not change significantly. After PRP injection, 23 women (7.4%) conceived spontaneously, 201 (64.8%) developed antral follicle(s) and attempted IVF, and 87 (27.8%) had no antral follicles and therefore did not receive additional treatment. Among the 201 women who attempted IVF, 82 (26.4% of total) developed embryos; 25 of these women preferred to cryopreserve embryos for transfer at a later stage, while 57 underwent embryo transfer resulting in 13 pregnancies (22.8% per transfer, 4% of total). In total, of the 311 women treated with PRP, 25 (8.0%) achieved livebirth/sustained implantation (spontaneously or after IVF), while another 25 (8.0%) cryopreserved embryos. Our findings suggest that in women with POI, intraovarian injection of autologous PRP might be considered as an alternative experimental treatment option.